Rafarma Pharmaceuticals develops new liposome-based medicine for targeted therapy

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has announced the development of a new drug for colon, pancreas and breast cancer treatment. An extremely promising medicine for the pharmaceutical industry is liposomes carrying a lipophilic prodrug of a widely used antitumor agent merphalan and equipped with tetrasaccharide Sialyl LewisX (SiaLeX).


The use of liposomes as an antitumor agent carrier has been discussed for a long time. It is known that liposomes reduce the toxicity of chemotherapeutic agents due to specific biodistribution between tissues and organs. At the same time, ensuring target delivery has always been challenging because tumor cells are well protected from blood flow drugs by the vascular and interstitial barrier.


Targeted therapy aimed at interacting with specific tumor receptors significantly limits the range of use of such drugs due to the presence of intratumoral heterogeneity: as the tumor progresses, many clones of cells are formed that do not express specific receptors and, therefore, are resistant to therapy.


Cytotoxic vector liposomes preclude this outcome. The carbohydrate ligand SiaLeX can recognize selectins present on the endothelium of tumor-feeding vessels, as well as lectins located on cancer cells. This feature determines the long-term prospects of SiaLeX for the therapy of oncological diseases.


Rafarma Pharmaceuticals sees considerable potential in liposome-based medicine development for targeted therapy. To date, the company has already developed a production scheme and has begun preclinical trials.


ABOUT RAFARMA PHARMACEUTICALS:

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. The business has had a reputation as a reliable manufacturer and distributor since 1930. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.


For more information, please visit https://www.noyarp.com


FORWARD-LOOKING STATEMENT:

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACTS:

RAFARMA PHARMACEUTICALS

Info@rafapharm.com

(307) 429-2029


Source: Rafarma Pharmaceuticals, Inc.